Prograf + Tacrolimus Hexal

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Pharmacokinetics Study in de Novo Kidney Transplantation

Conditions

Pharmacokinetics Study in de Novo Kidney Transplantation

Trial Timeline

Oct 17, 2012 โ†’ Aug 20, 2015

About Prograf + Tacrolimus Hexal

Prograf + Tacrolimus Hexal is a approved stage product being developed by Novartis for Pharmacokinetics Study in de Novo Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01649427. Target conditions include Pharmacokinetics Study in de Novo Kidney Transplantation.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01649427ApprovedCompleted

Competing Products

20 competing products in Pharmacokinetics Study in de Novo Kidney Transplantation

See all competitors